نتایج جستجو برای: trivalent vaccine

تعداد نتایج: 111876  

2011
Bohdan Nosyk Behnam Sharif Huiying Sun Curtis Cooper Aslam H. Anis

BACKGROUND Influenza vaccine immunogenicity is diminished in patients living with HIV/AIDS. We evaluated the cost-effectiveness and expected value of perfect information (EVPI) of three alternative influenza vaccine dosing strategies intended to increase immunogenicity in those patients. METHODS A randomized, multi-centered, controlled, vaccine trial was conducted at 12 CIHR Canadian HIV Tria...

2013
Dorothee Kieninger Eric Sheldon Wen-Yuan Lin Chong-Jen Yu Jose M Bayas Julian J Gabor Meral Esen Jose Luis Fernandez Roure Silvia Narejos Perez Carmen Alvarez Sanchez Yang Feng Carine Claeys Mathieu Peeters Bruce L Innis Varsha Jain

BACKGROUND Two antigenically distinct influenza B lineages have co-circulated since the 1980s, yet inactivated trivalent influenza vaccines (TIVs) include strains of influenza A/H1N1, A/H3N2, and only one influenza B from either the Victoria or Yamagata lineage. This means that exposure to B-lineage viruses mismatched to the TIV is frequent, reducing vaccine protection. Formulations including b...

2010
Matthew C. Johns Angelia A. Eick David L. Blazes Seung-eun Lee Christopher L. Perdue Robert Lipnick Kelly G. Vest Kevin L. Russell Robert F. DeFraites Jose L. Sanchez

INTRODUCTION A novel A/H1N1 virus is the cause of the present influenza pandemic; vaccination is a key countermeasure, however, few data assessing prior seasonal vaccine effectiveness (VE) against the pandemic strain of H1N1 (pH1N1) virus are available. MATERIALS AND METHODS Surveillance of influenza-related medical encounter data of active duty military service members stationed in the Unite...

2016
Aurélien Jamotte Chui Fung Chong Andrew Manton Bérengère Macabeo Mondher Toumi

BACKGROUND Annual trivalent influenza vaccines (TIV) containing three influenza strains (A/H1N1, A/H3N2, and one B) have been recommended for the prevention of influenza. However, worldwide co-circulation of two distinct B lineages (Victoria and Yamagata) and difficulties in predicting which lineage will predominate each season have led to the development of quadrivalent influenza vaccines (QIV...

2011
Jodie McVernon Karen Laurie Ian Barr Anne Kelso Maryanne Skeljo Terry Nolan

BACKGROUND Early outbreaks of the pandemic influenza A (H1N1) 2009 virus predominantly involved young children, who fuelled transmission through spread in homes and schools. Seroprevalence studies conducted on stored serum collections indicated low levels of antibody to the novel strain in this age group, leading many to recommend priority immunisation of paediatric populations. OBJECTIVES In...

2013
Joseph B. Domachowske Heidemarie Pankow-Culot Milagros Bautista Yang Feng Carine Claeys Mathieu Peeters Bruce L. Innis Varsha Jain

BACKGROUND Two antigenically distinct influenza B lineages have cocirculated since 2001, yet trivalent influenza vaccines (TIVs) contain 1 influenza B antigen, meaning lineage mismatch with the vaccine is frequent. We assessed a candidate inactivated quadrivalent influenza vaccine (QIV) containing both B lineages vs TIV in healthy children aged 3-17 years. METHODS Children were randomized 1:1...

2012
Maurizio Bonati Antonio Clavenna

Seasonal influenza is an important public health and medical challenge. Vaccination against influenza is recognized worldwide as the main strategy for prevention and control. The findings of meta-analyses, however, suggest that efficacy and effectiveness of influenza vaccines, both in people aged 65 years or older [1] and in children, are lower than believed [2]. These findings were recently co...

2013
Joanne M. Langley Alfonso Carmona Martinez Archana Chatterjee Scott A. Halperin Shelly McNeil Keith S. Reisinger Naresh Aggarwal Li-Min Huang Ching-Tien Peng José Garcia-Sicilia Ignacio Salamanca de la Cueva Fernando Cabañas Consuelo Treviño-Garza Miguel Angel Rodríguez-Weber Manuel de la O Vijayalakshmi Chandrasekaran Walthère Dewé Aixue Liu Bruce L. Innis Varsha K. Jain

BACKGROUND Mismatch between circulating influenza B viruses (Yamagata and Victoria lineages) and vaccine strains occurs frequently. METHODS In a randomized controlled trial, immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate (QIV) versus trivalent inactivated influenza vaccine (TIV)-Victoria(Vic) and TIV-Yamagata(Yam) in children 3-17 years of age was evaluat...

Journal: :Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2015
J Li-Kim-Moy J K Yin H Rashid G Khandaker C King N Wood K K Macartney C Jones R Booy

In 2010, increased febrile convulsions (FC) occurred after administration of inactivated trivalent influenza vaccine (TIV) in Australia. We systematically reviewed the rates of fever, FC and serious adverse events (SAEs) after TIV, focussing on published and unpublished clinical trial data from 2005 to 2012, and performed meta-analysis of fever rates. From 4,372 records in electronic databases,...

2017
Herve Caspard Raburn M. Mallory Jing Yu Christopher S. Ambrose

BACKGROUND This systematic review and meta-analysis describes and consolidates findings from all studies that assessed the effectiveness of live-attenuated influenza vaccine (LAIV) against laboratory-confirmed influenza since the 2009 pandemic in children and young adults. METHODS A MEDLINE search was conducted for articles published from January 1, 2010 to November 30, 2016. All original pub...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید